Prosecution Insights
Last updated: July 17, 2026
Application No. 18/018,422

SOS1 INHIBITORS

Non-Final OA §102§112
Filed
Jan 27, 2023
Priority
Jul 28, 2020 — provisional 63/057,563 +2 more
Examiner
DAVIS, BRIAN J
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mirati Therapeutics Inc.
OA Round
3 (Non-Final)
85%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
81%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allowance Rate
1336 granted / 1575 resolved
+24.8% vs TC avg
Minimal -4% lift
Without
With
+-4.2%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 8m
Avg Prosecution
47 currently pending
Career history
1612
Total Applications
across all art units

Statute-Specific Performance

§101
3.9%
-36.1% vs TC avg
§103
22.9%
-17.1% vs TC avg
§102
24.2%
-15.8% vs TC avg
§112
27.5%
-12.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1575 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 5/26/2026 has been entered. Claim Objections Withdrawn The objection to claim 33, outlined in the previous Office Action, has been overcome by inventor’s amendment. The amendment corrects the claim text as appropriate. 112 Rejections Withdrawn The rejection of claim 1 under 35 USC 112(b) or 35 USC 112 (pre-AIA ), second paragraph, outlined in the previous Office Action, has been overcome by inventor’s amendment. The amendment clarifies the claim as appropriate. The rejection of claim 8 under 35 USC 112(b) or 35 USC 112 (pre-AIA ), second paragraph, outlined in the previous Office Action, has been overcome by inventor’s amendment. The amendment clarifies the claim as appropriate. The rejection of claim 33 under 35 USC 112(b) or 35 USC 112 (pre-AIA ), second paragraph, outlined in the previous Office Action, has been overcome by inventor’s amendment. The amendment clarifies the claim as appropriate. The rejection of claim 55 under 35 USC 112(b) or 35 USC 112 (pre-AIA ), second paragraph, outlined in the previous Office Action, has been overcome by inventor’s amendment. The amendment clarifies the claim as appropriate (by rewriting the claim as an independent claim). The rejection of claims 3, 4, 34-36, 39-51, 53 and 54 under 35 USC 112(b) or 35 USC 112 (pre-AIA ), second paragraph, outlined in the previous Office Action (indefinite from indefinite), is withdrawn. The rejection is moot. Claim Rejections - 35 USC § 112(b), MAINTAINED The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 9-11 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. It is unclear why definitions for variables R2 and R9 are recited in the claims when no such variables are present in the diagramed structures or their corresponding variable definitions. Inventor states in the Remarks that the claims have been amended in order to overcome the rejection. However, the claims have not, in fact, been amended. The examiner again respectfully suggests deleting the definitions. (As was done for claim 8.) 102 Rejections Withdrawn The rejection of claim 8 under 35 USC 102(a)(1), outlined in the previous Office Action, has been overcome by inventor’s amendment. The amendment narrows the scope of the claim such that it no longer reads on the cited art. Allowable Subject Matter Claims 1, 3, 4, 8, 12, 13, 15, 16, 19-26, 33-36, 39-51, 53-55 are allowed. The subject matter of the remaining claims would be allowable once the 112 rejection maintained above has been overcome. The following is a statement of reasons for the indication of allowable subject matter: The closest prior art is the prior art of record. During the course of prosecution, inventor has narrowed the scope of the claimed subject matter such that it no longer reads on this cited art. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN J DAVIS whose telephone number is (571)272-0638. The examiner can normally be reached M-F 8:30-5:00 PM EDT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush, can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN J DAVIS/Primary Examiner, Art Unit 1614 6/2/2026
Read full office action

Prosecution Timeline

Jan 27, 2023
Application Filed
Aug 21, 2025
Non-Final Rejection mailed — §102, §112
Jan 22, 2026
Response Filed
Feb 24, 2026
Final Rejection mailed — §102, §112
May 26, 2026
Request for Continued Examination
May 27, 2026
Response after Non-Final Action
Jun 04, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678516
IMMUNOSTIMULATORY TOLL-LIKE RECEPTOR AGONIST-NANOPARTICLE FOR CANCER IMMUNOTHERAPY
2y 9m to grant Granted Jul 14, 2026
Patent 12673026
LIPOSOMAL COMPOSITIONS AND METHODS OF USE THEREOF FOR IMPROVED STABILITY, BIOAVAILABILITY & SUSTAINED RELEASE
2y 1m to grant Granted Jul 07, 2026
Patent 12667560
CO-ADMINISTRATION OF MIRDAMETINIB AND LIFIRAFENIB FOR USE IN TREATING CANCERS
3y 9m to grant Granted Jun 30, 2026
Patent 12667555
IMPROVED TREATMENT OF OVARIAN CANCER WITH NIROGACESTAT
2y 4m to grant Granted Jun 30, 2026
Patent 12667814
PREPARATION OF AN AMINO-FUNCTIONAL POLYORGANOSILOXANE EMULSION
2y 0m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
85%
Grant Probability
81%
With Interview (-4.2%)
1y 8m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1575 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month